Results 191 to 200 of about 1,447,276 (313)

Expanded genetic alphabet increases structural and chemical diversity of six-letter DNA for high-affinity protein-targeting aptamers. [PDF]

Nat Commun
Sawada K, Kimoto M, Matsunaga KI, Tan HP, Takayanagi R, Sano FK, Shuto Y, Hirano H, Kusakizako T, Itoh Y, Kise Y, Hirao I, Nureki O.   +12 more
europepmc   +1 more source

Stepwise protein targeting into plastoglobules are facilitated by three hydrophobic regions of rice phytoene synthase 2. [PDF]

Front Plant Sci, 2023
Yu JS, You MK, Lee YJ, Ha SH.
europepmc   +1 more source

Protein Targeting [PDF]

Journal of Medical Genetics, 1998
openaire   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation. [PDF]

Acta Pharm Sin B
Wu Y, Wang X, Sun X, Gao X, Zhang S, Shen J, Tian H, Chen X, Huang H, Jiang S, Zhang B, Zhang Y, Lu M, Zhang H, Sun Z, Liu R, Zhang H, Zhang MR, Hu K, Wang R.   +19 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Identification and antiviral mechanism of a novel chicken-derived interferon-related antiviral protein targeting PRDX1. [PDF]

PLoS Pathog
Chen J, Li P, Li L, Li J, Jiang Y, Zou W, Hao P, Gao Z, Hao J, Shi X, Fei D, Ma M, Wang G, Li C.   +13 more
europepmc   +1 more source

RecF protein targeting to postreplication (daughter strand) gaps I: DNA binding by RecF and RecFR. [PDF]

Nucleic Acids Res, 2023
Henry C, Mbele N, Cox MM.
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Protein-targeting reverse genetic approaches: the future of oocyte and preimplantation embryo research. [PDF]

Mol Hum Reprod
Camlin NJ.
europepmc   +1 more source